Low expression of novel biomarker RCSD1 predicts poor prognosis of lung adenocarcinoma

Lung adenocarcinoma(LUAD)is a highly malignant lung tumor.In patients with acute lymphoblastic leukemia,the RCSD domain containing 1(RCSD1)gene is translocated and fused with the ABL1 gene to form the RCSD1-ABL1 fusion gene,resulting in high chromosome instability.However,the role of RCDS1 in lung adenocarcinoma remains unclear.This study aimed to evaluate the relationship between the expression of RCSD1 in lung adenocarcinoma,clinical prognosis,biological processes involved,and immune infiltration.The lung cancer explorer database was used to conduct a meta-analysis on the study of RCSD1 in lung adenocarcinoma.We downloaded the sequencing data of the RCSD1 gene in lung adenocarcinoma for prognostic analysis.A receiver operating characteristic(ROC)curve was drawn to assess the diagnostic value of RCSD1 expression in LUAD.Using R language,univariate and multivariate COX regression analysis of the clinical data of RCSD1 in lung adenocarcinoma was carried out.The molecular biological process of RCSD1 in lung adenocarcinoma and the relationship between RCSD1 expression level and immune infiltration were analyzed.Different from the normal lung tissue,the expression level of RCSD1 in lung adenocarcinoma is decreased.Low expression of RCSD1 is related to different clinicopathological characteristics.RCSD1 participates in multiple immune-related pathways and is positively correlated with tumor immune infiltrating cells,immune phenotypes,and immune checkpoint expression.We reveal for the first time the prognostic role of RCSD1 in lung adenocarcinoma.Its mechanism of action may be involved in regulating immune infiltration and can serve as a potential biomarker of lung adenocarcinoma.